

د. سليمان الحبيب
DR SULAIMAN AL HABIB
المجموعة الطبية medical group



**Dr. Sulaiman Al Habib Medical Services Group Company
and its Subsidiaries
(Saudi Joint Stock Company)**

Condensed Consolidated Interim Financial Statements
For the three months period ended 31 March 2026





INDEX	Pages
Review report on the condensed consolidated interim financial statements	1
Condensed consolidated interim statement of financial position	2
Condensed consolidated interim statement of income	3
Condensed consolidated interim statement of comprehensive income	4
Condensed consolidated interim statement of changes in equity	5
Condensed consolidated interim statement of cash flows	6
Notes to the condensed consolidated interim financial statements	7-14



Report on review of condensed consolidated interim financial statements

To the shareholders of Dr. Sulaiman Al Habib Medical Services Group Company
(A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of Dr. Sulaiman Al Habib Medical Services Group Company (“the Company”) and its subsidiaries (collectively with the Company referred to as “the Group”) as at 31 March 2026, and the related condensed consolidated interim statements of income, comprehensive income, changes in equity and cash flows for the three-month period then ended, and other explanatory notes. The Board of Directors are responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”), as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, as endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, as endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with IAS 34, as endorsed in the Kingdom of Saudi Arabia.

PricewaterhouseCoopers

Khalid A. Mahdhar
License Number 368



3 May 2026
16 Dhu Al-Qi'dah 1447 H

PricewaterhouseCoopers Public Accountants
(Professional Limited Liability Company)
Laysen Valley Tower 12 & 13, King Khaled Road
T: +966 (11) 211 0400, F: +966 (11) 211 0401

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY AND ITS SUBSIDIARIES
(Saudi Joint Stock Company)
Condensed consolidated interim statement of financial position
As at 31 March 2026



		31 March 2026	31 December 2025
		ﷲ	ﷲ
	Note	(Unaudited)	(Audited)
Assets			
Current assets			
Cash and cash equivalents		2,415,362,769	2,281,635,206
Accounts receivable		1,629,351,872	1,622,406,728
Prepayments and other assets		448,529,749	494,936,466
Inventories		1,154,034,052	1,028,292,270
Total current assets		5,647,278,442	5,427,270,670
Non-current assets			
Investments in associates		176,309,575	175,256,312
Investments in Islamic Sukuk & other financial assets		369,220,200	300,000,000
Property and equipment	7	17,573,462,142	17,302,419,382
Total non-current assets		18,118,991,917	17,777,675,694
Total assets		23,766,270,359	23,204,946,364
Liabilities and equity			
Liabilities			
Current liabilities			
Current portion of long-term loans	11	70,567,042	96,039,119
Accounts payable		2,296,898,261	2,015,293,259
Accruals and other liabilities		2,450,986,858	2,411,307,826
Zakat and income tax payable		39,875,032	95,673,216
Current portion of lease liabilities		96,855,631	100,341,908
Total current liabilities		4,955,182,824	4,718,655,328
Non-current liabilities			
Long-term loans	11	8,975,777,314	8,734,566,320
Government grant		43,605,122	43,659,819
Lease liabilities		359,304,766	373,686,238
Employees' end-of-service benefits		945,369,460	905,699,043
Total non-current liabilities		10,324,056,662	10,057,611,420
Total liabilities		15,279,239,486	14,776,266,748
Equity			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Retained earnings		4,449,691,194	4,401,716,037
Equity attributable to equity holders of the Parent Company		7,949,691,194	7,901,716,037
Non-controlling interests		537,339,679	526,963,579
Total equity		8,487,030,873	8,428,679,616
Total liabilities and equity		23,766,270,359	23,204,946,364

The accompanying notes 1 to 16 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:
FAISAL AL NASSAR
CFO

APPROVED BY:
FAISAL AL NASSAR
CEO

APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY AND ITS SUBSIDIARIES
(Saudi Joint Stock Company)
Condensed consolidated interim statement of income
For the three months period ended 31 March 2026



	For the three months period ended	
	31 March 2026	31 March 2025
	ﷲ	ﷲ
Note	(Unaudited)	(Unaudited)
Revenue	3,435,762,489	3,157,779,769
Cost of revenue	(2,479,792,517)	(2,129,469,373)
Gross profit	955,969,972	1,028,310,396
Selling and marketing expenses	(95,428,910)	(132,376,360)
General and administrative expenses	(272,796,001)	(270,005,881)
Operating profit	587,745,061	625,928,155
Share of income of associates	3,057,193	3,857,363
Finance costs	(104,109,924)	(78,648,702)
Other income	52,855,547	38,573,271
Profit before zakat and income tax	539,547,877	589,710,087
Zakat and income tax	(26,153,797)	(9,927,245)
Profit for the period	513,394,080	579,782,842
Profit for the period attributable to:		
Equity holders of the Parent Company	503,292,741	557,009,075
Non-controlling interests	10,101,339	22,773,767
	513,394,080	579,782,842
Earnings per share:		
Basic and diluted earnings per share from profit for the period attributable to equity holders of the Parent Company	12	1.44
		1.59

The accompanying notes 1 to 16 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:
FAISAL AL NASSAR
CFO

APPROVED BY:
FAISAL AL NASSAR
CEO

APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY AND ITS SUBSIDIARIES
(Saudi Joint Stock Company)
Condensed consolidated interim statement of comprehensive income
For the three months period ended 31 March 2026



	For the three months period ended	
	31 March 2026	31 March 2025
	ﷲ	ﷲ
	(Unaudited)	(Unaudited)
Profit for the period	513,394,080	579,782,842
Other comprehensive income		
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>		
Remeasurement gain (loss) on defined benefit obligations	3,457,177	(10,177,035)
Other comprehensive income (loss) for the period	3,457,177	(10,177,035)
Total comprehensive income for the period	516,851,257	569,605,807
Total comprehensive income for the period attributable to:		
Equity holders of the Parent Company	506,475,157	546,496,674
Non-controlling interests	10,376,100	23,109,133
	516,851,257	569,605,807

The accompanying notes 1 to 16 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:
FAISAL AL NASSAR
CFO

APPROVED BY:
FAISAL AL NASSAR
CEO

APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY AND ITS SUBSIDIARIES
(Saudi Joint Stock Company)
Condensed consolidated interim statement of changes in equity
For the three months period ended 31 March 2026



	Attributable to equity holders of the Parent Company			Non-controlling interests	Total equity
	Issued and paid-up share capital	Retained earnings	Total		
	ﷲ	ﷲ	ﷲ	ﷲ	ﷲ
As at 1 January 2026 (Audited)	3,500,000,000	4,401,716,037	7,901,716,037	526,963,579	8,428,679,616
Profit for the period	-	503,292,741	503,292,741	10,101,339	513,394,080
Other comprehensive income	-	3,182,416	3,182,416	274,761	3,457,177
Total comprehensive income	-	506,475,157	506,475,157	10,376,100	516,851,257
Dividends (note 10)	-	(458,500,000)	(458,500,000)	-	(458,500,000)
As at 31 March 2026 (Unaudited)	3,500,000,000	4,449,691,194	7,949,691,194	537,339,679	8,487,030,873
As at 1 January 2025 (Audited)	3,500,000,000	3,675,142,519	7,175,142,519	437,505,578	7,612,648,097
Profit for the period	-	557,009,075	557,009,075	22,773,767	579,782,842
Other comprehensive (loss) income	-	(10,512,401)	(10,512,401)	335,366	(10,177,035)
Total comprehensive income	-	546,496,674	546,496,674	23,109,133	569,605,807
Dividends (note 10)	-	(430,500,000)	(430,500,000)	-	(430,500,000)
Changes in non-controlling interests	-	-	-	(2,764)	(2,764)
As at 31 March 2025 (Unaudited)	3,500,000,000	3,791,139,193	7,291,139,193	460,611,947	7,751,751,140

The accompanying notes 1 to 16 form an integral part of these condensed consolidated interim financial statements.


APPROVED BY:
FAISAL AL NASSAR
CFO


APPROVED BY:
FAISAL AL NASSAR
CEO


APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY AND ITS SUBSIDIARIES
(Saudi Joint Stock Company)
Condensed consolidated interim statement of cash flows
For the three months period ended 31 March 2026



	2026 ﷲ	2025 ﷲ
	(Unaudited)	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before zakat and income tax	539,547,877	589,710,087
Adjustments for non-cash items:		
Depreciation	212,921,188	151,547,093
Share of income of associates	(3,057,193)	(3,857,363)
Provisions	22,073,445	64,266,636
Finance costs	104,109,924	78,648,702
Employees' end-of-service benefits	55,160,509	36,281,702
	930,755,750	916,596,857
Working capital changes:		
Accounts receivable	(27,148,227)	(132,916,847)
Inventories	(127,612,144)	(82,613,746)
Prepayments and other assets	46,744,634	(155,673,561)
Accounts payable	281,605,002	188,844,405
Accruals and other liabilities	44,463,802	82,798,486
Cash generated from operating activities	1,148,808,817	817,035,594
Zakat and income tax paid	(81,951,981)	(76,208,352)
Employees' end-of-service benefits paid	(12,032,915)	(7,235,745)
Net cash from operating activities	1,054,823,921	733,591,497
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(472,627,235)	(934,321,624)
Investment in associates	(15,132,652)	-
Investments in Islamic Sukuk & other financial assets	(57,416,743)	-
Dividends from associates	5,333,125	-
Net cash used in investing activities	(539,843,505)	(934,321,624)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from long-term loans	400,000,000	400,000,000
Repayment of long-term loans	(185,507,138)	-
Finance costs paid	(107,703,336)	(79,600,677)
Lease liabilities paid	(29,542,379)	(31,661,135)
Dividends paid	(458,500,000)	(430,500,000)
Non-controlling interest	-	(2,764)
Net cash used in financing activities	(381,252,853)	(141,764,576)
Net increase (decrease) in cash and cash equivalents	133,727,563	(342,494,703)
Cash and cash equivalents at the beginning of the period	2,281,635,206	2,890,702,697
Cash and cash equivalents at the end of the period	2,415,362,769	2,548,207,994
Non-cash transactions:		
Recognition of right-of-use assets and lease liabilities	11,674,630	51,688,478
Transfer from prepayments and other assets to property and equipment	-	39,978,296

The accompanying notes 1 to 16 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:
FAISAL AL NASSAR
CFO

APPROVED BY:
FAISAL AL NASSAR
CEO

APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN



1 Corporate information and activities

Dr. Sulaiman Al Habib Medical Services Group Company (the "Company") (a Saudi Joint Stock Company) is registered in Riyadh, under commercial registration number 1010118330 dated 11 Jumada al-thani 1414H (corresponding to 25 November 1993). The registered office is located at Olaya District, P.O. Box 301578, Riyadh 11372, Kingdom of Saudi Arabia (the "Kingdom" and/or "KSA"), and the Company was listed on the Saudi Stock Exchange (Tadawul) on 22 Rajab 1441H (corresponding to 17 March 2020).

The activities of the Company and its subsidiaries (collectively referred to as "the Group") are to provide private health services and ancillary services for its operations in the Kingdom and the region through the establishment, management, and operation of hospitals, general and specialized medical complexes, day surgery centers, pharmaceutical facilities, and other ancillary areas which include providing services of Home health care, specialized medical laboratories, technology services and information systems, providing facility maintenance services, Tele-medicine services, revenue cycle management services, medical equipment maintenance services, and real estate activity.

The Company has a branch located in Riyadh, Kingdom of Saudi Arabia, "Branch of Dr. Sulaiman Al Habib Medical Services Group Company" ("the Branch") under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The Branch is engaged in the activities of retail sales of medical devices, equipment, and supplies, as well as operating pharmaceutical warehouses and general warehouses that store a range of goods.

The number of shares is (350,000,000) and the share value is ﷲ 10.

The condensed consolidated interim financial statements include the financial information of the branch mentioned above and subsidiaries mentioned in note 3.

2 Basis of preparation

2.1 Statement of compliance

These condensed consolidated interim financial statements as at and for the three-month period ended 31 March 2026 have been prepared in accordance with International Accounting Standard 34 – "Interim Financial Reporting" (IAS 34) as endorsed in the Kingdom of Saudi Arabia ("KSA") and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA") (collectively referred to as "IAS-34 as endorsed in KSA").

The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

The condensed consolidated interim financial statements are considered an integral part of the whole fiscal year, however, the results of operations for the interim period may not be a fair indication of the results of the full year operations.

2.2 Basis of measurement

These condensed consolidated interim financial statements are prepared on a historical cost basis except for employees' end of service benefits are recognized at the present value of future obligations using the Projected Unit Credit Method.

2.3 Functional and presentation currency

The condensed consolidated interim financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Group and all values are rounded to the nearest one Saudi Riyal, except when otherwise indicated.



2 Basis of preparation (continued)

2.4 Use of judgement and estimates

In preparing these condensed consolidated interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual Consolidated Financial Statements.

3 Basis of consolidation

These condensed consolidated interim financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as "the Group"), mainly domiciled in the Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE") as at 31 March 2026 and 31 December 2025:

	Country of incorporation and business	Activities / Services	Ownership %	
			31 March 2026	31 December 2025
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare	100%	100%
Al Gharb Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarat Diagnostic Medical Company	KSA	Laboratory	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahaba for IT & Communication Company	KSA	IT Support	100%	100%
Rawabet Medical Company	KSA	Medical and Telemedicine	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiyah Hospital for Healthcare Company	KSA	Hospital	100%	100%
Taswyat Administrative Company	KSA	Revenue cycle management	100%	100%
Al Marakez Al Awwalyah for Healthcare Company	KSA	Primary Healthcare centers	100%	100%
Wrass Real Estate Company	KSA	Real Estate	100%	100%
Flow Medical Company	KSA	Medical equipment services	100%	100%
Sehat Al Kharj for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Gharb for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Shamal for Healthcare Company	KSA	Hospital	100%	100%
Sehat Al Hamra for Healthcare Company	KSA	Hospital	100%	100%
Wrass for Operation and Maintenance Company	KSA	Ancillary	100%	100%
Dr. Sulaiman Al Habib for Education Company	KSA	Higher Education	100%	100%
Bawabat Al Sharq for Healthcare Company	KSA	Hospital	100%	100%
Sehat Al Sahel Company	KSA	Hospital	100%	100%



3 Basis of consolidation (continued)

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the period are included in the condensed consolidated interim financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

4 Consistent application of accounting policies

The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of new standards effective as of 1 January 2026. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.



5 New and amended standards and interpretations

5.1 Amendments applied by the Group on 1 January 2026 and have no material effect on the condensed consolidated interim financial statements are as follows:

- Amendments to the Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7 (issued on 30 May 2024 and effective for annual periods beginning on or after 1 January 2026).

5.2 The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group's condensed consolidated interim financial statements are disclosed below. The Group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

- IFRS 18 Presentation and Disclosure in Financial Statements (Issued on 9 April 2024 and effective for annual periods beginning on or after 1 January 2027) - IFRS 18 will replace IAS 1 Presentation of financial statements, introducing new requirements that will help to achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users. Even though IFRS 18 will not impact the recognition or measurement of items in the financial statements, its impacts on presentation and disclosure are expected to be pervasive, in particular those related to the statement of financial performance and providing management-defined performance measures within the financial statements. Management is currently assessing the detailed implications of applying the new standard on the Group's consolidated financial statements.
- IFRS 19 Subsidiaries without Public Accountability: Disclosures (Issued on 9 May 2024 and effective for annual periods beginning on or after 1 January 2027)



6 Segment Information

Operating segments are determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM").

The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit are consistent measure within the Group.

The identified key segments are Hospitals / Healthcare Facilities, Pharmacies and HMG Solutions / Others (which includes IT support services, laboratory services, home healthcare services, medical equipment services, revenue cycle management and real estate). The segment results (revenue and gross profit) for the three months period ended 31 March 2026 and the reconciliation of the segment measures to the respective statutory items included in the condensed consolidated interim financial statements are as follows:

SAR Million	Hospitals / Healthcare Facilities	Pharmacies	Solutions / Others	Total
For the three months period ended 31 March 2026 (Unaudited)				
Revenue	2,624	736	76	3,436
Gross profit	700	230	26	956
As at 31 March 2026 (Unaudited)				
Total assets	19,384	1,003	3,379	23,766
Total liabilities	9,954	1,179	4,146	15,279
For the three months period ended 31 March 2025 (Unaudited)				
Revenue	2,433	657	68	3,158
Gross profit	799	192	37	1,028
As at 31 December 2025 (Audited)				
Total assets	18,920	697	3,588	23,205
Total liabilities	10,219	836	3,721	14,776

7 Property and equipment

	31 March 2026 SAR (Unaudited)	31 December 2025 SAR (Audited)
Property and equipment	17,056,599,148	16,768,187,836
Right-of-use assets *	516,862,994	534,231,546
	17,573,462,142	17,302,419,382

* Right-of-use assets mainly pertain to lease of lands and accommodation for the Group employees.



8 Related party disclosures

Related parties represent shareholders, Directors and key management personnel of the Group, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of these transactions are approved by the Group's management.

Related party transactions

Significant transactions and balances with related parties are in the ordinary course of business which are included in the condensed consolidated interim financial statements are summarized as follows:

Related party	Nature of transaction	For the three months period ended	
		31 March 2026	31 March 2025
		ﷲ	ﷲ
Board of Directors	Purchases and services	860,493	460,494
Affiliates Parties	Purchases and services	29,641,791	32,264,131
Affiliates Parties	Capital work-in-progress	602,841	4,497,295
Associates Parties	Revenue	24,363,369	18,978,827
Associates Parties	Purchases and services	2,497,643	3,586,703

Affiliates Parties refer to entities under common ownership with the Group.

Associates Parties refer to entities over which the Group has significant influence, typically defined as owning 20% to 50% of the voting shares.

Compensation of key management personnel of the Group

Key management personnel of the Group comprise of the Board of Directors and key members of management having authority and responsibility for planning, directing and controlling the activities of the Group.

	For the three months period ended	
	31 March 2026	31 March 2025
	ﷲ	ﷲ
Short-term employee benefits	3,510,000	3,840,000
Board of Directors and its committees remuneration	755,000	745,000
Post-employment and medical benefits	263,750	320,000
Total compensation paid to key management personnel	4,528,750	4,905,000

9 Zakat and income tax

9.1 Zakat

The following table summarizes the zakat status for the Group and its subsidiaries on reporting date:

Zakat Status	Company ownership %	Zakat return filed up to	Zakat certificate received up to	Final Zakat assessment received up to
Consolidated zakat returns for the Co. and its subsidiaries	100	2025	2025	2024
Sehat Al Sharq Medical Limited Co.	50	2025	2025	2020
Gharb Jeddah Hospital Co.	50	2025	2025	2022
Al Wosta Medical Limited Co.	50	2025	2025	2022
Asharq Alawsat Pharmacies Co. ⁽¹⁾	100	2025	2025	2023

⁽¹⁾ During the year 2024, the other party assigned their less than 1% share to the Company, which directly and indirectly owns 100% of the entity, leading to its segregation into a separate Zakat pool.



9 Zakat and income tax (continued)

9.2 Income tax

UAE Corporate Income Tax Law On 9 December 2022, the UAE Ministry of Finance released Federal Decree-Law No. 47 of 2022 on the Taxation of Corporations and Businesses (Corporate Tax Law or the Law) to enact a Federal corporate tax (CT) regime in the UAE. The CT regime is effective for accounting periods beginning on or after 1 June 2023. The Group subsidiary in Dubai is subject to the provisions of the UAE CT Law with effect from 1 January 2024.

10 Dividend

On 14 February 2026 the Board of Directors resolved to distribute interim dividends of ₪ 458,500,000 at ₪ 1.31 per share representing 13.1% of the nominal value of the share for the 4th quarter of 2025 (during Q1 of the year 2025: Interim dividends of ₪ 430,500,000 at ₪ 1.23 per share representing 12.3% of the nominal value of the share, for the 4th quarter of 2024), based on the authorization to distribute interim dividends to the shareholders, quarterly or semi-annually, for the fiscal year 2025 which was granted to the Board of Directors by the Ordinary General Assembly which was held on Sunday 6 Dhu al-Qi'dah 1446H (corresponding to 4 May 2025).

11 Long-term loans

	31 March 2026	31 December 2025
	₪	₪
	(Unaudited)	(Audited)
Current-portion of loans and borrowings:		
Loans from local banks (i)	36,363,636	61,835,713
Loans from Ministry of Finance (ii)	34,203,406	34,203,406
	70,567,042	96,039,119
Non-current portion of loans and borrowings:		
Loans from local banks (i)	8,717,148,490	8,477,183,551
Loans from Ministry of Finance (ii)	258,628,824	257,382,769
	8,975,777,314	8,734,566,320

i) Loans from local banks

The Group is financed through Islamic facilities in the form of long-term loans (Murabaha / Tawarruq) from local banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SAIBOR" plus an agreed margin. The facilities are secured by corporate promissory notes.

ii) Loans from Ministry of Finance (MoF)

The Group's long-term financing includes MoF non-interest-bearing loans to finance the capital expenditures related to the Company and its subsidiaries. The loan repayment instalments are settled on equal yearly installments. Certain assets are pledged against the loans obtained from the MoF.



12 Earnings per share

Basic and diluted earnings per share ("EPS") is calculated by dividing the profit for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the profit for the period attributable to equity holders of the parent Company and share data used in the basic and diluted EPS computations:

	For the three months period ended	
	31 March 2026	31 March 2025
	ﷲ	ﷲ
Profit for the period attributable to equity holders of the parent Company	503,292,741	557,009,075
Weighted average number of ordinary shares	350,000,000	350,000,000
<i>Basic and diluted earnings per share from profit for the period attributable to equity holders of the parent Company</i>	1.44	1.59

13 Fair values

Financial instruments comprise financial assets and financial liabilities.

Financial assets consist of cash and cash equivalents, accounts receivable, Investments in Islamic Sukuk & other financial assets, contract assets and others. Financial liabilities consist of long-term loans, accounts payable, lease liabilities, accruals and other liabilities.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date.

14 Subsequent events

Management has evaluated events occurring after the reporting period up to the date of approval of the condensed consolidated interim financial statements and concluded that there are no events that require adjustment to or disclosure in the condensed consolidated interim financial statements.

15 Geopolitical developments

The Group continues to monitor the regional geopolitical developments and their potential impact on Saudi Arabia and the broader GCC environment given that the majority of the Group's operations are conducted mainly in the Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE"). While the situation remains evolving, the Group maintains a robust operational framework to manage associated risks. These developments have not had a material impact on the Group's condensed consolidated interim financial statements for the period ended 31 March 2026; however, given the evolving nature of the conflict, the potential long-term impact on the Group's business will continue to be assessed on future reporting dates.

16 Approval of the condensed consolidated interim financial statements

The condensed consolidated interim financial statements of the Group for the three months period ended 31 March 2026 were approved for issuance by the Board of Directors on 15th Dhu Al-Qi'dah 1447 H (corresponding to 2nd May 2026).